EM905

EM905 is a synthetic, non-antibiotic 12-membered macrolide derivative developed by researchers at Kitasato University, including Satoshi Ōmura. It is a derivative of the parent compound EM900, chemically identified as de(3′-N-methyl)-3′-N-(p-chlorobenzyl)-9-dihydro-pseudoerythromycin A 6,9-epoxide. EM905 was designed to retain the anti-inflammatory and immunomodulatory properties characteristic of certain macrolides while being devoid of antibacterial activity, thereby minimizing the risk of developing bacterial resistance during chronic treatment. Its mechanism of action involves the promotion of monocyte-to-macrophage differentiation. Preclinical studies have shown that EM905 is effective in mouse models of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, demonstrating therapeutic potential at low doses comparable to the standard drug sulfasalazine.

Other names

de(3'-N-methyl)-3'-N-(p-chlorobenzyl)-9-dihydro-pseudoerythromycin A 6,9-epoxide